Company Filing History:
Years Active: 1997-2002
Title: Joseph Polazzi: Innovator in Hematopoietic Stem Cell Expansion
Introduction
Joseph Polazzi, an accomplished inventor located in Chesterfield, MO, has made significant contributions to the field of biomedical research through his innovative work on interleukin-3 mutant polypeptides. With a total of two patents to his name, Polazzi's research focuses on enhancing the ex-vivo expansion of hematopoietic stem cells, which hold great promise in regenerative medicine.
Latest Patents
Polazzi's latest patent, titled "Methods of using interleukin-3 (IL-3) mutant polypeptides for ex-vivo expansion of hematopoietic stem cells", delves into the development of recombinant human interleukin-3 variant proteins. These hIL-3 muteins are engineered with specific amino acid substitutions and deletions, resulting in polypeptides that may exhibit biological activities comparable to or improved over that of natural hIL-3. The invention importantly includes pharmaceutical compositions using these muteins and methodologies for their recombinant production through microbial expression systems. Furthermore, the patent describes deletion mutants with variable amino acid deletions at both the N- and C-termini, introducing enhanced side effect profiles which could broaden their therapeutic applications.
Career Highlights
Throughout his career, Joseph Polazzi has worked for notable companies such as G.D. Searle & Company and Pharmacia Corporation. His experience at these organizations has equipped him with a deep understanding of pharmaceutical research and development, contributing to his innovative endeavors in the field.
Collaborations
Collaboration plays a vital role in Polazzi's work, as he has partnered with distinguished colleagues such as S. Christopher Bauer and Mark Allen Abrams. Their combined expertise enhances the quality and impact of their research initiatives.
Conclusion
Joseph Polazzi stands out as a prominent inventor in the realm of biomedical innovation. Through his patents and collaborative efforts, he continues to advance the understanding and application of interleukin-3 in stem cell research, potentially leading to transformative therapeutic solutions in the future.